Johnson & Johnson (JNJ) news

Older JNJ news events, each with the realized, point-in-time move the market made — page 5 of 10. Back to the JNJ overview → · Full JNJ reaction history →

Latest news

Recent JNJ events, each with its measured reaction. (Page 5 of 10.)

DateHeadlineEventSource5-minTo close
Form 10-Q JOHNSON & JOHNSON For: Jun 29SEC filing · Form 10-QSEC EDGAR-0.18%-0.85%
Johnson & Johnson showcases latest advancements in Alzheimer's research at AAIC 2025Press releasePR Newswire-0.19%+0.04%
Johnson & Johnson to Participate in the 2025 Wells Fargo Healthcare ConferencePress releaseBusiness Wire-0.18%-0.85%
Form 13F-HR JOHNSON & JOHNSON For: Jun 30SEC filing · Form 13F-HRSEC EDGAR-0.01%+0.85%
Johnson & Johnson seeks first icotrokinra U.S. FDA approval aiming to revolutionize treatment paradigm for adults and adolescents with plaque psoriasisPress releasePR Newswire-0.50%+0.30%
Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancerPress releasePR Newswire-0.08%-0.62%
Dean Omar Branham Shirley Attorney Named Among Nation’s Top Future Legal LeadersPress releaseBusiness Wire+0.00%-0.59%
Form 8-K JOHNSON & JOHNSON For: Jul 16SEC filing · Form 8-KSEC EDGAR+1.26%+2.99%
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025Press releaseBusiness Wire+1.26%+2.99%
Johnson & Johnson Reports Q2 2025 Results; Raises 2025 OutlookPress releaseBusiness Wire+1.26%+2.99%
Supplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placeboPress releasePR Newswire+0.07%+0.85%
Form 11-K JOHNSON & JOHNSON For: Dec 31SEC filing · Form 11-KSEC EDGAR+0.01%+0.42%
IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)Press releasePR Newswire+0.37%+0.81%
Johnson & Johnson Hit With $8M Verdict in Massachusetts Mesothelioma Talc LawsuitPress releaseBusiness Wire+0.24%-0.69%
Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary diseasePress releasePR Newswire-0.38%-0.77%
Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphomaPress releasePR Newswire+0.10%-0.09%
New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemiaPress releasePR Newswire+0.07%+0.41%
New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritisPress releasePR Newswire+0.01%-0.67%
Form 8-K JOHNSON & JOHNSON For: Jun 10SEC filing · Form 8-KSEC EDGAR+0.01%-0.67%
Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of DirectorsPress releaseBusiness Wire+0.01%-0.67%
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativityPress releasePR Newswire-0.06%-0.28%
Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patientsPress releasePR Newswire-0.08%-0.30%
Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPCPress releasePR Newswire+0.12%-0.24%
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myelomaPress releasePR Newswire-0.07%-0.29%
Form SD JOHNSON & JOHNSONSEC filing · Form SDSEC EDGAR+0.63%+1.21%
Johnson & Johnson to Host Investor Conference Call on Second-Quarter ResultsPress releaseBusiness Wire+0.63%+1.21%
Products That Count Announces Winners of the 2025 Q1 Product Manager AwardsPress releasePR Web-0.03%-0.27%
Jessica Dean Named to National Law Journal’s 2025 Elite Women of the Plaintiffs BarPress releaseBusiness Wire-0.06%+0.32%
FDA Panel Reiterates the Cancer Risks of TalcPress releaseBusiness Wire-0.15%-0.04%
Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions ConferencePress releaseBusiness Wire+0.09%-0.06%
Dean Omar Branham Shirley Recognized Twice Among ALM’s 2024 Top 100 VerdictsPress releaseBusiness Wire+0.06%+0.33%
U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myelomaPress releasePR Newswire+0.27%-0.01%
Statement On $147M Verdict for AMDR Member Innovative Health Against Johnson & Johnson’s Biosense Webster Medical Technology UnitPress releaseBusiness Wire+0.22%+0.40%
Nachawati Law Group Files New Ovarian Cancer Lawsuits Against Johnson & Johnson After Latest Bankruptcy Ploy FailsPress releaseBusiness Wire-0.17%+1.11%
Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferencePress releaseBusiness Wire+0.09%+0.88%
Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasisPress releasePR Newswire-0.01%-0.77%
Johnson & Johnson expands efforts to champion the nursing workforce globallyPress releaseBusiness Wire+0.25%-0.10%
Form 13F-HR JOHNSON & JOHNSON For: Mar 31SEC filing · Form 13F-HRSEC EDGAR+0.25%-0.10%
TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two yearsPress releasePR Newswire-0.84%-1.07%
TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeksPress releasePR Newswire-0.84%-1.07%
Form 8-K JOHNSON & JOHNSON For: Apr 24SEC filing · Form 8-KSEC EDGAR-0.69%-0.35%
Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)Press releasePR Newswire-0.93%-1.07%
Products That Count Announces Winners of the 2025 Q1 Product AwardsPress releasePR Web-0.04%+0.42%
Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions ConferencePress releaseBusiness Wire-0.19%+0.30%
Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBCPress releasePR Newswire-0.33%-0.10%
Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancerPress releasePR Newswire-0.33%-0.10%
Roswell Park Expert to Share Promising Results on New Immunotherapy Approach in Non-Small Cell Lung CancerPress releasePR Web-0.33%-0.10%
Form 10-Q JOHNSON & JOHNSON For: Mar 30SEC filing · Form 10-QSEC EDGAR-0.91%-0.56%
Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUAPress releasePR Newswire-0.26%-0.69%
Roswell Park Researchers to Discuss Recent Discoveries and Critical Issues in Oncology at AACR 2025Press releasePR Web-0.25%-0.66%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground